GlassScriptPhysician profile
Monteza Modaber
NPI 1528412368
$2,327.67
in general payments reported to CMS, 2019-2025
19 companies · $580 in 2025
The $580 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $312 · 2022: $764 · 2023: $472 · 2024: $200 · 2025: $580.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,252.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,251.74 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $662.65 | 2021-2024 | |
| Neurocrine Biosciences, INC. | $368.47 | 2025 | |
| Medtronic, INC. | $213.68 | 2022-2023 | Linq II |
| Ceribell, INC. | $133.64 | 2025 | Pocket Eeg Device |
| Teva Pharmaceuticals USA, INC. | $122.33 | 2021-2023 | Austedo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $117.30 | 2021 | |
| Alexion Pharmaceuticals, INC. | $115.37 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $107.03 | 2021-2022 | |
| Neurasignal INC. | $95.00 | 2024 | |
| Medical Device Business Services, INC. | $78.01 | 2025 | Embotrap |
| Biogen, INC. | $67.43 | 2021-2022 | |
| Acadia Pharmaceuticals INC | $61.74 | 2022-2023 | Nuplazid |
| Horizon Therapeutics Plc | $54.39 | 2022 | |
| Emd Serono, INC. | $44.60 | 2022-2023 | Mavenclad |
| Ucb, INC. | $26.25 | 2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $23.98 | 2022 | |
| Lilly USA, LLC | $19.77 | 2022 | |
| Impel Pharmaceuticals INC. | $16.03 | 2022 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Monteza Modaber listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.